Inhibikase Therapeutics Inc (IKT) — Net Asset Momentum
Inhibikase Therapeutics Inc (IKT) recorded a net asset momentum of 764.2% as of December 2024, with net assets of $94.87 Million USD. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See IKT book value for net asset value and shareholders' equity analysis.
YoY Momentum
Current Net Assets
Years of Data
Country
Inhibikase Therapeutics Inc Net Asset Momentum (2016–2024)
This chart tracks Inhibikase Therapeutics Inc's year-over-year net asset growth across 9 annual reporting periods from 2016 to 2024. The most recent momentum reading is +764.2%, with net assets of $94.87 Million USD as of December 2024. Check Inhibikase Therapeutics Inc tangible book value ratio to evaluate the tangible quality of the company's equity base.
Annual Net Asset History for Inhibikase Therapeutics Inc (2016–2024)
The table below shows the complete annual net asset history for Inhibikase Therapeutics Inc from 2016 to 2024, covering 9 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and overall valuation, see how much is Inhibikase Therapeutics Inc worth.
| Year | Net Assets (USD) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2024 | $94.87 Million | $98.60 Million | $3.73 Million | ▲ +764.2% |
| 2023 | $10.98 Million | $14.51 Million | $3.53 Million | ▼ -47.8% |
| 2022 | $21.04 Million | $24.94 Million | $3.90 Million | ▼ -45.2% |
| 2021 | $38.42 Million | $42.47 Million | $4.05 Million | ▲ +292.6% |
| 2020 | $9.78 Million | $14.78 Million | $5.00 Million | ▲ +317.9% |
| 2019 | $-4.49 Million | $38.25K | $4.53 Million | ▼ -477.1% |
| 2018 | $-777.97K | $2.85 Million | $3.62 Million | ▲ +46.0% |
| 2017 | $-1.44 Million | $285.17K | $1.73 Million | ▼ -6.6% |
| 2016 | $-1.35 Million | $162.93K | $1.51 Million | — |